Skip to main content

AbbVie Appoints New General Manager in U.K.

Press release   •   Jul 19, 2019 13:03 BST

Maidenhead, UK, 19th July 2019 – AbbVie, a global biopharmaceutical company, today announced that Todd Manning has been named General Manager, AbbVie U.K. This change will be effective 1st September 2019.

Todd moves to the UK from his current position within the company as General Manager, AbbVie Ireland. Elected to the Irish Pharmaceutical Healthcare Association (IPHA) strategy board in 2016 and to the Board of Directors in 2018, he has held the positions of Deputy Vice President and Chair of the Finance Committee. He also served on several working groups including Market Access and Biotherapeutics.

Since joining Abbott in 2004 he has held roles of increasing responsibility; Director, Immunology, Ireland; Director, Immunology, Canada; HCV Senior Commercial Director, Western Europe & Canada. Prior to joining the organisation, Todd was with TAP Pharmaceuticals, Inc. where he held a variety of commercial sales and marketing positions.

Todd earned a Bachelor’s degree in Chemistry from the College of Holy Cross in Massachusetts.

Todd will succeed Jérôme Bouyer, UK General Manager since July 2017, who is appointed Vice President, AbbVie Eastern Europe Middle East and Africa (EEMEA).

###

Media:

Gwenan White, Communications Director AbbVie U.K.

+44 787 6391 429

gwenan.white@abbvie.com 

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world. For more information about AbbVie, please visit us at www.abbvie.co.uk. Follow us on twitter: @abbvieuk.